Grifols

GRFSApproved

Founded 1909grifols.com

Grifols is a Spanish multinational pharmaceutical and chemical company that develops plasma-derived medicines and other biopharmaceuticals for patients with chronic and rare diseases. Founded in 1909 in Barcelona, the company has grown into a global leader in plasma collection and fractionation, with operations spanning biopharma, diagnostics, bio supplies, and hospital healthcare solutions. The company is publicly traded and has been recognized by TIME magazine and Forbes as one of the world's best companies and employers for multiple consecutive years.

Market Cap

$2.0B

Founded

1909

Employees

10,000-15,000

Focus

BiologicsDiagnostics

GRFS · Stock Price

USD 7.582.95 (-28.02%)

Historical price data

AI Company Overview

Technology Platform

Grifols leverages deep expertise in plasma science and fractionation technology to develop life-saving plasma-derived medicines, along with diagnostic solutions and hospital healthcare systems. The company's integrated platform spans from plasma collection through final product delivery.

Pipeline Snapshot

102

102 drugs in pipeline, 36 in Phase 3

Drug	Indication	Stage
IGSC 20%	Primary Immunodeficiency	Approved
Alphanate SD/HT	Von Willebrand Disease	Approved
Albumin	Cirrhosis	Approved
Alphanate SD/HT	Severe Hemophilia A	Approved
(100 ml of Albumin 25%)	Hypotension During Dialysis	Approved

FDA Approved Drugs

SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINERANDAMay 25, 2017

Opportunities

Grifols has significant growth opportunities through expanding its plasma collection network globally, advancing innovative neurology research programs like CHRONOS-PD and AMBAR®, and leveraging the growing demand for plasma-derived therapeutics in emerging markets.

Risk Factors

Key risks include regulatory challenges in the biologics industry, dependence on plasma supply and donor availability, and increasing competition from biosimilars and alternative treatments.

The company also faces potential manufacturing and quality control challenges inherent in plasma-derived medicine production.

Competitive Landscape

Grifols competes with major plasma companies like CSL Behring, Takeda, and Octapharma, but differentiates itself through its integrated business model spanning the entire value chain, strong global presence, and innovative focus on neurodegenerative diseases research.

Publications

Patents

Pipeline

102

FDA Approvals